Noxopharm is a Group comprising Noxopharm Ltd, Nyrada Inc, and NoxAsia Ltd with offices in Sydney, New York and Hong Kong. The Group's drug pipeline contains 4 drug candidates: Veyonda®, NYX-104, NYX-205, NYX-330. Veyonda® is being developed as an enhancer of radiotherapy across a range of cancers, including prostate cancer patients being treated with both standard external beam radiotherapy and intravenous radionuclide (177lutetium-PSMA-617) therapy; NYX-104 is a neuroprotectant being developed to limit secondary brain damage (glutamate-induced excitotoxicity) following ischaemic stroke and concussion; NYX-205 is an anti-inflammatory being developed for the treatment of peripheral neuropathy associated with diabetes and chemotherapy; NYX-330 is a PCSK9 inhibitor being developed for the treatment of high blood LDL cholesterol levels that fail to respond adequately to statin therapy alone.

Veyonda® is the first pipeline product, previously known as NOX66. It is currently in clinical trials. It has also been trialled as an enhancer of chemotherapy across a range of cancers.

Media Releases

Latest Company News


Videos

Dec 2019 03:50 PM
Noxopharm (ASX:NOX) DARRT-1 pr..
03 Dec 2019 - Noxopharm Limited (ASX:NOX) Executive Chairman & CEO, Dr Graham Kelly, discusses clinical results from the company's Phase 1b clinical DARRT-1 trial for its lead product candidate, Veyonda, with low-dose radiotherapy.

Contact Information